Protocol Title: KEYMAKER-U01 Substudy 01F: A Phase 1b/2 Umbrella Study With Rolling Arms of Investigational Agents for Previously Treated of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations

Status

Not yet recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512248-47-00

Enrollment

Registered

2026-03-04

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small Cell Lung Cancer (NSCLC)

Brief summary

Number of Participants Who Experience a Dose Limiting Toxicity (DLT), Number of Participants Who Experience an Adverse Event (AE), Number of Participants Who Discontinue Study Treatment Due to an AE, Objective Response Rate (ORR)

Detailed description

Duration of Response (DOR), Progression-Free Survival (PFS), Area Under the Curve From Time 0 to the End of the Dosing Interval (AUC tau), Maximum Plasma Concentration (Cmax), Minimum Observed Concentration (Ctrough)

Interventions

DRUG-

DRUGCETUXIMAB

DRUGMK-1084

DRUGMK-1022

DRUGMK-2870

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Number of Participants Who Experience a Dose Limiting Toxicity (DLT), Number of Participants Who Experience an Adverse Event (AE), Number of Participants Who Discontinue Study Treatment Due to an AE, Objective Response Rate (ORR)	—

Secondary

Measure	Time frame
Duration of Response (DOR), Progression-Free Survival (PFS), Area Under the Curve From Time 0 to the End of the Dosing Interval (AUC tau), Maximum Plasma Concentration (Cmax), Minimum Observed Concentration (Ctrough)	—

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 6, 2026